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ABSTRACT
Genome-wide association studies (GWAS) linking polymorphisms in ATG16L1 with susceptibility to
inflammatory bowel disease (IBD) have prompted mucosal immunologists to investigate the functional
roles of macroautophagy/autophagy in different cell types in the gut. Here we present a recent study that
addressed 2 key questions: in which cell type is autophagy deficiency most detrimental during chronic
colitis and what is the functional role of autophagy in those cells? We report that autophagy in intestinal
epithelial cells (IECs) acts to limit intestinal inflammation by protecting them from TNF-induced apoptosis
and we discuss the potential implications for IBD treatment.
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Inflammatory bowel disease is a complex inflammatory disor-
der of the gastrointestinal tract thought to arise from a dysregu-
lated immune response towards the microbiota. Although
many pathogenic networks underlying disease development
have been identified, the exact etiology is unknown, reflecting
the complexity and diversity of the disease manifestations.
Polymorphisms in several autophagy-related genes, such as
ATG16L1 and IRGM, have been linked to IBD by GWAS.
Autophagy is a versatile cellular degradation pathway impli-
cated in many stress response mechanisms fundamentally
important in nearly every cell type. Therefore, the genetic links
identified by GWAS do not give any mechanistic information
about the functional consequences, or about the cell types in
which the autophagy pathway is important during chronic
intestinal inflammation.
Recently, we addressed this issue by utilizing a Cre-lox
genetic approach to generate transgenic mouse lines in which
the IBD-associated autophagy gene Atg16l1 was selectively
ablated in distinct cellular compartments. To assess the impact
on chronic intestinal inflammation, we used an IBD model trig-
gered by infection with the opportunistic bacterial pathogen
Helicobacter hepaticus and simultaneous inhibition of the regu-
latory arm of the immune response with anti-IL10R blocking
antibody. Although previous studies in other systems suggest
that autophagy can limit release of pro-inflammatory cytokines
by myeloid cells (macrophages and dendritic cells), we found
that selective ablation of Atg16l1 in the myeloid compartments
has little impact on this bacterially triggered chronic intestinal
inflammation. In contrast, mice with selective ablation of
autophagy in IECs (Atg16l1VC mice) exhibit severely exacer-
bated intestinal pathology, characterized by increased accumu-
lation of CD4+ T cells in the lamina propria and elevated levels
of pro-inflammatory cytokines.
The increased pathology in Atg16l1VC mice is also accompa-
nied by a higher number of apoptotic cells in the epithelium.
Increased epithelial cell death could result in impaired barrier
function leading to exacerbated pathology; however, it could
also be just a consequence of the elevated inflammatory cyto-
kines present in Atg16l1VC mice. This led us to investigate
whether autophagy intrinsically regulates cytokine-induced
apoptosis in IECs. Using complementary approaches, we found
that autophagy directly controls apoptosis in epithelial cells.
First, utilizing the recently developed ‘organoid’ system to cul-
ture primary IECs ex vivo, we found that Atg16l1-deficient
IECs show increased induction of apoptosis following exposure
to pro-inflammatory cytokines (TNF + IFNG/IFNg) compared
to wild-type IECs. Second, in vivo injection of TNF induces
higher numbers of apoptotic IECs in the small intestine of
Atg16l1VC mice compared to wild-type mice. Of note, increased
apoptosis in autophagy-deficient IECs is only observed follow-
ing inflammatory cytokine stimulation or in the context of
chronic inflammation; at steady-state, IECs cope well with the
lack of autophagy in regard to proliferation and differentiation,
and exhibit normal inflammatory responses.
It has been previously recognized that TNF induces IEC
apoptosis in the context of IBD and in murine disease models.
Our results show that autophagy-deficient IECs are much more
sensitive to cytokine-induced apoptosis. Therefore we won-
dered whether TNF blockade would ameliorate the increased
IEC death and intestinal pathology observed in colitic
Atg16l1VC mice. Indeed, TNF blockade significantly attenuates
disease severity and reduces IEC apoptosis in Atg16l1VC mice.
These findings confirm that the exacerbated pathology in
Atg16l1VC mice is largely driven by TNF-induced IEC apoptosis
(Figure 1).
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TNF is a key cytokine in IBD pathology, and treatment
strategies targeting TNF signaling are one of the most effective
treatment regimens. Despite the proven importance of the cyto-
kine, it is not completely understood how TNF mediates its
pathogenic effects and thus how TNF blockade acts to promote
disease resolution. Of note, there is considerable heterogeneity
among IBD patients in terms of disease manifestations, inflam-
matory profile and treatment responsiveness. Indeed, although
anti-TNF therapies can be very effective, approximately 40% of
IBD patients do not respond to anti-TNF treatment and many
more become refractory to treatment. TNF blockers are expen-
sive therapeutics and, to date, it is not possible to predict
whether a given patient will respond to anti-TNF therapies.
Our results suggest that IBD patients harboring risk alleles that
sensitize the epithelial barrier to apoptosis may be more likely
to respond to anti-TNF therapies, and if confirmed, this could
lead to more efficient deployment of such treatments.
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Figure 1. Autophagy limits cytokine-induced apoptosis of intestinal epithelial cells during chronic intestinal inflammation. Upper panels: Schematic representation of the
protective role of autophagy in IECs during chronic intestinal inflammation. Lower panels: Representative immunofluorescence staining of apoptotic cells (TUNEL, red),
counterstain (WGA, green) and nuclei (DAPI, blue) in colon sections taken from wild-type mice, Atg16l1VC mice and Atg16l1VC mice treated with a blocking antibody
against TNF (anti-TNF), during experimental IBD. In wild-type IECs the apoptosis pathway is limited by autophagy, resulting in only a few apoptotic cells and moderate
levels of inflammation (left panels). Selective ablation of autophagy in IECs leads to increased epithelial apoptosis, resulting in exacerbated inflammatory pathology (mid-
dle panels). These can be ameliorated by blocking TNF, the main driver of apoptosis (right panels). Lower panels reproduced with permission from Elsevier (color online).
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